Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Johnson and Johnson
Merck
Baxter
McKesson

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR ACTIVELLA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Activella

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00919919 ↗ Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Unknown status Ferring Pharmaceuticals Phase 2 2009-06-01 The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.
NCT00919919 ↗ Efficacy and Tolerability Study of Progesterone Vaginal Tablets (Endometrin®) in Menopausal Women Treated by Estrogen Unknown status Rabin Medical Center Phase 2 2009-06-01 The objective of the study is to confirm that the efficacy of vaginal progesterone is at least as good as oral progesterone in order to protect the endometrium of uncontrolled proliferation and prevent endometrial cancer.
NCT01157182 ↗ Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fasting Conditions Completed Teva Pharmaceuticals USA Phase 1 2007-02-01 The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fasting conditions.
NCT01181726 ↗ Estradiol/Norethindrone Acetate Tablets, 1/0.5 mg Under Fed Conditions Completed Teva Pharmaceuticals USA Phase 1 2007-01-01 The objective of this study was to determine and compare the rate and extent of absorption of norethindrone and unconjugated estradiol from a test formulation of Estradiol/Norethindrone Acetate Tablets, 1 mg/0.5 mg versus the reference Activella® (1 mg estradiol/0.5 mg norethindrone acetate) Tablets under fed conditions.
NCT01817530 ↗ Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) Completed AbbVie Phase 2 2013-04-08 This is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of elagolix alone and in combination with add-back therapy versus placebo on heavy menstrual bleeding in premenopausal women 18 to 51 years of age with uterine fibroids.
NCT02693002 ↗ Estrogen Diastolic Heart Failure Terminated Gretchen Wells Phase 4 2016-02-01 Peri-menopausal women will be randomized to hormone replacement therapy or placebo for 12 weeks to determine if markers of systolic and diastolic function change by echocardiography as well as laboratory markers of heart failure, including b-type natriuretic peptide (BNP).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Activella

Condition Name

Condition Name for Activella
Intervention Trials
Healthy 2
Menopause 1
Uterine Fibroids 1
Endometrial Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Activella
Intervention Trials
Endometrial Neoplasms 1
Uterine Hemorrhage 1
Endometrial Hyperplasia 1
Myofibroma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Activella

Trials by Country

Trials by Country for Activella
Location Trials
United States 66
Canada 5
Puerto Rico 2
Israel 1
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Activella
Location Trials
Kentucky 3
Oregon 2
Florida 2
Georgia 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Activella

Clinical Trial Phase

Clinical Trial Phase for Activella
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Activella
Clinical Trial Phase Trials
Completed 3
Active, not recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Activella

Sponsor Name

Sponsor Name for Activella
Sponsor Trials
Teva Pharmaceuticals USA 2
AbbVie 2
Ferring Pharmaceuticals 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Activella
Sponsor Trials
Industry 5
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
AstraZeneca
McKinsey
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.